These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 8755580

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations.
    Rossel M, Pasini A, Chappuis S, Geneste O, Fournier L, Schuffenecker I, Takahashi M, van Grunsven LA, Urdiales JL, Rudkin BB, Lenoir GM, Billaud M.
    Oncogene; 1997 Jan 23; 14(3):265-75. PubMed ID: 9018112
    [Abstract] [Full Text] [Related]

  • 3. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P.
    Verh Dtsch Ges Pathol; 1995 Jan 23; 79():L-LV. PubMed ID: 8600671
    [Abstract] [Full Text] [Related]

  • 4. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase.
    Marshall GM, Peaston AE, Hocker JE, Smith SA, Hansford LM, Tobias V, Norris MD, Haber M, Smith DP, Lorenzo MJ, Ponder BA, Hancock JF.
    Cancer Res; 1997 Dec 01; 57(23):5399-405. PubMed ID: 9393766
    [Abstract] [Full Text] [Related]

  • 5. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D, Melillo RM, Monaco C, Visconti R, Fenzi G, Vecchio G, Fusco A, Santoro M.
    Cancer Res; 2001 Feb 15; 61(4):1426-31. PubMed ID: 11245446
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.
    Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH.
    Science; 1995 Jan 20; 267(5196):381-3. PubMed ID: 7824936
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ligand stimulation of a Ret chimeric receptor carrying the activating mutation responsible for the multiple endocrine neoplasia type 2B.
    Rizzo C, Califano D, Colucci-D'Amato GL, De Vita G, D'Alessio A, Dathan NA, Fusco A, Monaco C, Santelli G, Vecchio G, Santoro M, de Franciscis V.
    J Biol Chem; 1996 Nov 15; 271(46):29497-501. PubMed ID: 8910618
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2.
    Ponder BA.
    Cancer Surv; 1995 Nov 15; 25():195-205. PubMed ID: 8718519
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2.
    Pausova Z, Soliman E, Amizuka N, Janicic N, Konrad EM, Arnold A, Goltzman D, Hendy GN.
    J Clin Endocrinol Metab; 1996 Jul 15; 81(7):2711-8. PubMed ID: 8675600
    [Abstract] [Full Text] [Related]

  • 17. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
    Carlomagno F, Melillo RM, Visconti R, Salvatore G, De Vita G, Lupoli G, Yu Y, Jing S, Vecchio G, Fusco A, Santoro M.
    Endocrinology; 1998 Aug 15; 139(8):3613-9. PubMed ID: 9681515
    [Abstract] [Full Text] [Related]

  • 18. Characterization of ret oncogenic activation in MEN2 inherited cancer syndromes.
    Xing S, Smanik PA, Oglesbee MJ, Trosko JE, Mazzaferri EL, Jhiang SM.
    Endocrinology; 1996 May 15; 137(5):1512-9. PubMed ID: 8612479
    [Abstract] [Full Text] [Related]

  • 19. Absence of MEN2A- or 2B-type RET mutations in primary neuroblastoma tumour tissue.
    Peaston AE, Camacho ML, Norris MD, Haber M, Marsh DJ, Robinson BG, Hyland VJ, Marshall GM.
    Mol Cell Probes; 1998 Aug 15; 12(4):239-42. PubMed ID: 9727201
    [Abstract] [Full Text] [Related]

  • 20. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.
    Carlomagno F, Salvatore G, Cirafici AM, De Vita G, Melillo RM, de Franciscis V, Billaud M, Fusco A, Santoro M.
    Cancer Res; 1997 Feb 01; 57(3):391-5. PubMed ID: 9012462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.